IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy

People with HIV experienced a decrease in bone density at the hip and spine during their first 2 years after starting antiretroviral therapy (ART). While bone loss slowed after 96 weeks, it continued to decline more rapidly among HIV-positive people compared with the usual age-related bone loss seen in HIV-negative people over 7 years, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]

The Trans-Pacific Partnership trade agreement, now under consideration, will heavily impact the availability of medications for HIV and viral hepatitis, both in middle-income countries and in high-income countries such as Canada that rely on generic drugs, advocates said at a Médecins Sans Frontières media briefing at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

IAS 2015: Peer-Led Intervention Lowers HIV Infections Among Drug Injectors in Ukraine

A cluster-randomized trial in Ukraine has shown that a peer education project reduced new HIV infections in people who inject drugs by 41%, researchers reported at the recent 8th Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

Half of U.S. Gay Men Using Dating Apps Have Interacted with a PrEP User

Almost half of American gay men recruited to participate in a survey via advertising on a major mobile phone dating app say that at least one potential sexual partner has said that he was taking HIV pre-exposure prophylaxis (PrEP), and even more have interacted with someone who said that he was HIV-positive but had an undetectable viral load. Many of these potential partners were looking for sex without a condom, according to the survey results, published in the August 21 online edition ofJournal of Acquired Immune Deficiency Syndromes.

alt

Read more:

IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART

A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.

alt

Read more:

More Articles...